We are excited to announce that the U.S. FDA has allowed Phase III clinical evaluation of our allogeneic, injectable disc progenitor #celltherapy (IDCT) for painful lumbar #degenerativediscdisease to proceed. Subject enrollment expected to begin Q4 2024. bit.ly/3xX8cv4

DiscGenics Chairman & CEO @flagg_flanagan to present at #CanaccordGenuity 2024 Musculoskeletal Conference prn.to/4bxu7ro #aaos2024

We are proud to announce that we have partnered with the U.S. Department of Veterans Affairs (VA) to explore the synergy of our Discogenic Cells with the VA's advanced disc-like angle ply structure. Pushing boundaries in spinal health! prnewswire.com/news-releases…

We're thrilled to announce that our CEO, @flagg_flanagan, will be presenting at the East-West BioPharma Summit from Oct 2-4 and the 2023 Cell & Gene Meeting on the Mesa from Oct 10-12. Learn more about the event in our press release! prnewswire.com/news-releases…

Thrilled to share highlights from our recent podcast with Merge Medical! Dive into the innovative world of DiscGenics and discover the transformative potential of IDCT. A must-listen for those passionate about the future of spinal health! #IDCT #RegenerativeMedicine #SpinalHealth

FDA grants Regenerative Medicine Advanced Therapy (#RMAT) designation to IDCT because of its potential to address the unmet medical needs of millions of patients with painful #degenerativediscdisease! bit.ly/IDCT_RMAT

Clinical Trial Results: Discogenic progenitor #celltherapy (IDCT) safely increased disc volume & provided rapid, durable improvements in low back pain, function, quality of life & pain med use out to 2 years in patients with #degenerativediscdisease. prn.to/3R1jhjM

Our CEO & Chairman @FlanaganFlagg will present an update on our recently completed US clinical study evaluating IDCT for #degenerativediscdisease at the 41st Annual J.P. Morgan Healthcare Conference on Wed., Jan 11, 2023 at 3:30PM. #JPM23 #JPM2023 prn.to/3i9REIc

Matthew F. Gornet, MD will present 2-year clinical data from #DiscGenics study of injectable discogenic progenitor #celltherapy for #degenerativediscdisease at the @NASSspine annual meeting in Chicago tomorrow! bit.ly/3rMMrXX #NASS22 #NASS2022

If you’re attending the @alliancerm #CGMesa22, don’t miss CEO Flagg Flanagan’s on-demand update on #DiscGenics first-in-human clinical study of its allogeneic discogenic progenitor #celltherapy for #degenerativediscdisease. bit.ly/3SGluB2

#DiscGenics Senior Process Engineer is in Dublin this week presenting at the Global Bioprocessing, Bioanalytics & ATMP Manufacturing Congress (@lifesciences_GE) on container closure integrity testing for #celltherapy. global-engage.com/event/biop…

Positive interim clin data for allogeneic #celltherapy for #degenerativediscdisease presented at #SpineSummit2022. High dose IDCT well tolerated, resulted in statistically significant, clinically meaningful improvements in pain, function & quality of life bit.ly/3tcqRwf

Our CEO & Chairman Flagg Flanagan will present an update on our US and Japanese clinical programs evaluating IDCT for #degenerativediscdisease at the 40th Annual J.P. Morgan Healthcare Conference on Tues., Jan 11, 2022 at 9:00AM EST. #JPM22 #JPM2022 bit.ly/DGxJPM22

Congratulations to our Chairman & CEO Flagg Flanagan who was recognized by @GoldmanSachs for #entrepreneurship at 2021 Builders + Innovators Summit. #GSInnovator bit.ly/DiscGenicsGSInnovator

We are pleased to announce our participation in #CGMesa21 this week. Our Chairman & CEO Flagg Flanagan will give an update on the company’s U.S. and Japanese clinical programs evaluating IDCT for #degenerativediscdisease TODAY at 3:15PM PT. Learn more meetingonthemesa.com

Very excited to announce we have completed enrollment in our Japanese clinical study of our #celltherapy for #discdegeneration. Meanwhile in the U.S., all currently enrolled trial subjects have completed their one-year study visits. bit.ly/3tW5rmr